BridGene Biosciences is a biotechnology company pioneering the discovery and development of innovative small-molecule drugs that target traditionally undruggable targets. Leveraging its proprietary IMTAC(TM) chemoproteomic platform, BridGene screens covalent small molecules against the entire proteome in live cells to identify novel binding sites and drug candidates for high-value targets.
Leadership & Board
Current Number of Employees30
Current LinkedIn Followers5,321
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$28M
Total Amount Raised$28M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$28M
Latest Funding Amount$28M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
BridGene Biosciences had 30 employees as of October 5, 2026. The number of employees increased by 0 (0.00%) week-over-week.
30Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
BridGene Biosciences had 5,321 followers as of October 5, 2026. The number of followers increased by 2 (0.04%) week-over-week.
5,321Latest Followers Count
2(0.04%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.